Time to Think about HLA-Based Diagnostics in Lung Cancer?
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
received:
02
08
2023
revised:
29
08
2023
accepted:
08
09
2023
medline:
4
12
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
ppublish
Résumé
HLA evolutionary divergence reflects the ability to recognize diverse neoantigens as non-self, and as a biomarker is conceptually distinct from programmed cell death ligand 1 expression and tumor mutation burden. HLA-based assays to predict benefit from immunotherapy in lung cancer require prospective validation. See related article by Jiang et al., p. 4830.
Identifiants
pubmed: 37756560
pii: 729268
doi: 10.1158/1078-0432.CCR-23-2152
doi:
Substances chimiques
Biomarkers, Tumor
0
B7-H1 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4706-4708Informations de copyright
©2023 American Association for Cancer Research.